TPSAB1 expression	Melanoma	TPSAB1 expression	Melanoma	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3
CD9 expression	Melanoma	CD9 expression	Melanoma	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3
CSF2 expression	Melanoma	CSF2 expression	Melanoma	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3
STAT2 expression	Melanoma	STAT2 expression	Melanoma	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3	ex-vivo autologous dendritic cells vaccine Sensitive: C3 – Early Trials ex-vivo autologous dendritic cells vaccine Sensitive : C3

TLR4 antagonist

Associations(4)